Soleno Therapeutics, Inc.

NasdaqCM:SLNO Stock Report

Market Cap: US$1.9b

Soleno Therapeutics Management

Management criteria checks 2/4

Soleno Therapeutics' CEO is Anish Bhatnagar, appointed in Jan 2017, has a tenure of 7.92 years. total yearly compensation is $4.12M, comprised of 13.5% salary and 86.5% bonuses, including company stock and options. directly owns 0.1% of the company’s shares, worth $2.01M. The average tenure of the management team and the board of directors is 0.9 years and 5.5 years respectively.

Key information

Anish Bhatnagar

Chief executive officer

US$4.1m

Total compensation

CEO salary percentage13.5%
CEO tenure7.9yrs
CEO ownership0.1%
Management average tenureless than a year
Board average tenure5.5yrs

Recent management updates

Recent updates

Companies Like Soleno Therapeutics (NASDAQ:SLNO) Can Afford To Invest In Growth

Nov 08
Companies Like Soleno Therapeutics (NASDAQ:SLNO) Can Afford To Invest In Growth

Soleno Therapeutics Nears FDA Decision: Strong Buy Targeting PWS Hyperphagia Treatments

Oct 10

We're Not Worried About Soleno Therapeutics' (NASDAQ:SLNO) Cash Burn

Mar 08
We're Not Worried About Soleno Therapeutics' (NASDAQ:SLNO) Cash Burn

Here's Why We're Watching Soleno Therapeutics' (NASDAQ:SLNO) Cash Burn Situation

Sep 20
Here's Why We're Watching Soleno Therapeutics' (NASDAQ:SLNO) Cash Burn Situation

Soleno sheds 13% as 1-for-15 reverse stock split takes effect

Aug 26

Companies Like Soleno Therapeutics (NASDAQ:SLNO) Could Be Quite Risky

Aug 12
Companies Like Soleno Therapeutics (NASDAQ:SLNO) Could Be Quite Risky

Soleno Therapeutics surges 49% on regulatory pathway for Prader-Willi syndrome treatment

Jul 20

Here's Why Soleno Therapeutics (NASDAQ:SLNO) Must Use Its Cash Wisely

May 10
Here's Why Soleno Therapeutics (NASDAQ:SLNO) Must Use Its Cash Wisely

We're A Little Worried About Soleno Therapeutics' (NASDAQ:SLNO) Cash Burn Rate

Jan 24
We're A Little Worried About Soleno Therapeutics' (NASDAQ:SLNO) Cash Burn Rate

Soleno shares soar on FDA Orphan Drug status for Glycogen Storage Disease treatment

Jun 02

Will Soleno Therapeutics (NASDAQ:SLNO) Spend Its Cash Wisely?

Mar 23
Will Soleno Therapeutics (NASDAQ:SLNO) Spend Its Cash Wisely?

Need To Know: Soleno Therapeutics, Inc. (NASDAQ:SLNO) Insiders Have Been Buying Shares

Jan 29
Need To Know: Soleno Therapeutics, Inc. (NASDAQ:SLNO) Insiders Have Been Buying Shares

Soleno Therapeutics: Could Be Big Fish In The Small Pond

Jan 08

CEO Compensation Analysis

How has Anish Bhatnagar's remuneration changed compared to Soleno Therapeutics's earnings?
DateTotal CompensationSalaryCompany Earnings
Sep 30 2024n/an/a

-US$131m

Jun 30 2024n/an/a

-US$65m

Mar 31 2024n/an/a

-US$52m

Dec 31 2023US$4mUS$557k

-US$39m

Sep 30 2023n/an/a

-US$33m

Jun 30 2023n/an/a

-US$28m

Mar 31 2023n/an/a

-US$27m

Dec 31 2022US$1mUS$557k

-US$24m

Sep 30 2022n/an/a

-US$21m

Jun 30 2022n/an/a

-US$23m

Mar 31 2022n/an/a

-US$28m

Dec 31 2021US$4mUS$538k

-US$31m

Sep 30 2021n/an/a

-US$31m

Jun 30 2021n/an/a

-US$31m

Mar 31 2021n/an/a

-US$28m

Dec 31 2020US$3mUS$504k

-US$25m

Sep 30 2020n/an/a

-US$36m

Jun 30 2020n/an/a

-US$27m

Mar 31 2020n/an/a

-US$30m

Dec 31 2019US$822kUS$470k

-US$31m

Sep 30 2019n/an/a

-US$16m

Jun 30 2019n/an/a

-US$19m

Mar 31 2019n/an/a

-US$16m

Dec 31 2018US$952kUS$460k

-US$12m

Sep 30 2018n/an/a

-US$16m

Jun 30 2018n/an/a

-US$17m

Mar 31 2018n/an/a

-US$13m

Dec 31 2017US$1mUS$446k

-US$12m

Compensation vs Market: Anish's total compensation ($USD4.12M) is about average for companies of similar size in the US market ($USD5.51M).

Compensation vs Earnings: Anish's compensation has increased whilst the company is unprofitable.

CEO

Anish Bhatnagar (54 yo)

7.9yrs

Tenure

US$4,116,434

Compensation

Dr. Anish Bhatnagar, M.D. has been Chief Executive Officer and Director of Soleno Therapeutics, Inc. since 2017 and serves as its President and Chief Operating Officer. Prior to Soleno, Dr. Bhatnagar serve...

Leadership Team

NamePositionTenureCompensationOwnership
Anish Bhatnagar
President7.9yrsUS$4.12m0.10%
$ 2.0m
James MacKaness
Chief Financial Officer5.1yrsUS$1.21m0.070%
$ 1.4m
Patricia Hirano
Senior Vice President of Regulatory Affairsno dataUS$1.03m0.091%
$ 1.8m
Jesse Schumaker
General Counselless than a yearno datano data
Lauren Budesheim
Vice President of Peopleless than a yearno datano data
Kristen Yen
Senior Vice President of Clinical Operationsno dataUS$821.67k0.027%
$ 529.3k
Neil Cowen
Senior Vice President of Drug Development7.8yrsno datano data
Meredith Manning
Chief Commercial Officerless than a yearno datano data
Michael Huang
Senior Vice President of Clinical Development1.1yrsno datano data
Raymond W. Urbanski
Chief Development Officerless than a yearno datano data
Mitchell Nagao
Senior Vice President of Medical Affairsless than a yearno datano data

0.9yrs

Average Tenure

55yo

Average Age

Experienced Management: SLNO's management team is not considered experienced ( 0.9 years average tenure), which suggests a new team.

Board Members

NamePositionTenureCompensationOwnership
Anish Bhatnagar
President10.8yrsUS$4.12m0.10%
$ 2.0m
James Arthur Geraghty
Member of Advisory Boardless than a yearno datano data
William Harris
Independent Director10.5yrsUS$111.87k0.021%
$ 402.1k
Thomas Casale
Member of Advisory Boardno datano datano data
Andrew Sinclair
Independent Director6yrsUS$51.87k0.015%
$ 293.8k
Robert Christensen
Member of Advisory Boardno datano datano data
Vinod Bhutani
Member of Advisory Boardno datano datano data
Birgitte Volck
Independent Director5.5yrsUS$102.87k0.016%
$ 318.3k
Glenis Scadding
Member of Advisory Boardno datano datano data
Matthew Pauls
Lead Independent Director1.3yrsUS$70.53k0%
$ 0
Shamim Ruff
Chair of the Development Advisory Boardless than a yearno datano data
David Stevenson
Member of Advisory Boardno datano datano data

5.5yrs

Average Tenure

62yo

Average Age

Experienced Board: SLNO's board of directors are considered experienced (5.5 years average tenure).

Company Analysis and Financial Data Status

DataLast Updated (UTC time)
Company Analysis2024/12/22 09:53
End of Day Share Price 2024/12/20 00:00
Earnings2024/09/30
Annual Earnings2023/12/31

Data Sources

The data used in our company analysis is from S&P Global Market Intelligence LLC. The following data is used in our analysis model to generate this report. Data is normalised which can introduce a delay from the source being available.

PackageDataTimeframeExample US Source *
Company Financials10 years
  • Income statement
  • Cash flow statement
  • Balance sheet
Analyst Consensus Estimates+3 years
  • Forecast financials
  • Analyst price targets
Market Prices30 years
  • Stock prices
  • Dividends, Splits and Actions
Ownership10 years
  • Top shareholders
  • Insider trading
Management10 years
  • Leadership team
  • Board of directors
Key Developments10 years
  • Company announcements

* example for US securities, for non-US equivalent regulatory forms and sources are used.

Unless specified all financial data is based on a yearly period but updated quarterly. This is known as Trailing Twelve Month (TTM) or Last Twelve Month (LTM) Data. Learn more here.

Analysis Model and Snowflake

Details of the analysis model used to generate this report is available on our Github page, we also have guides on how to use our reports and tutorials on Youtube.

Learn about the world class team who designed and built the Simply Wall St analysis model.

Industry and Sector Metrics

Our industry and section metrics are calculated every 6 hours by Simply Wall St, details of our process are available on .

Analyst Sources

Soleno Therapeutics, Inc. is covered by 12 analysts. 8 of those analysts submitted the estimates of revenue or earnings used as inputs to our report. Analysts submissions are updated throughout the day.

AnalystInstitution
Brian SkorneyBaird
Kristen KluskaCantor Fitzgerald & Co.
François BriseboisCraig-Hallum Capital Group LLC